In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critical global health issue tightly linked with the One Health concept, which recognises that human and animal health are inextricably linked, and that diseases are transmitted from humans to animals and vice versa. One Health also encompasses the environment as another link between humans and animals and a potential source and reservoir of AMR. Antimicrobial resistance is a growing global health concern and threatens the future treatment and health of humans and animals. In addition, AMR limits our ability to achieve several of the UN Sustainable Development Goals (SDGs). The global challenge to address AMR goes beyond the production of new antibiotics and therapies. Reducing demand for new antibiotics through public awareness, infection prevention and control, prudent and rational use of antibiotics for humans and animals, as well as effective diagnosis and surveillance of antibiotic-resistant infections and monitoring antibiotic use, are crucial when dealing with this problem globally. The transmission and spread of AMR in and between One Health compartments is complex, which emphasises the need for comprehensive interventions to reverse the trend of increasing human and animal infections resistant to treatment. The ERA-NET Cofund JPIAMR-ACTION will tackle this central challenge by supporting research and innovation for the development and testing of strategies and methodologies to reduce the transmission and spread of AMR within a full One Health spectrum. The JPIAMR-ACTION co-funded call and other activities will be instrumental in producing new innovative approaches, and advancing existing actions towards the development of new and improved interventions to inhibit or limit the development of AMR in humans, animals and the environment.

The vision of FutureFoodS is to collectively achieve environmentally-friendly, socially secure, fair and economically viable healthy and safe Food Systems (FS) for Europe. FutureFoodS gather 87 partners from 22 EU Member States, 6 Associated Countries and 1 third country. FutureFoodS includes public and private actors, policy makers, foundations, locally, sub-nationally, nationally, EU-widely. All these FutureFoodS partners are fully aligned on the vision for the Partnership and the methodology for its implementation in line with SDG17 and EU Green Deal components. This vision has been broken down into general (GO), specific (SO) and operational (OO) objectives applying across the 4 R&I areas and 4 transversal activities identified by the FutureFoods consortium in its stable draft Strategic Research and Innovation Agenda (SRIA) which constitutes the strategic backbone of the project. The four GO cover: GO1 - Functioning of FS; GO2 - System approaches; GO3 - Inclusive government; GO4 - Co-creation cases. These GO have then been translated into SO prioritised in line with the timescale and resources of the Partnership: SO1 - Change the way we eat; SO2- Change the way we process and supply food, SO3 - Change the way we connect with FSs and SO4 - Change the way we govern FS. In addition, 6 interconnected OO have been set: OO1- Pooling R&I resources and programming; OO2 - Operational FS Observatory; OO3 - Active FS knowledge Hub of FS Labs; OO4 - Functioning knowledge sharing and scaling mechanisms; OO5- Revisiting the SRIA; OO6 - Promoting, supporting, widening & gathering FS various communities. The objectives implemented in the 8 WPs of FutureFoodS will exert impact directly or indirectly in most of the destinations of Horizon Europe’s Cluster 6 2023-2024 work programme and particularly for the topic destination ‘Fair, healthy and environment-friendly FS from primary production to consumption’ echoing to the main EU and World FS policies & strategies.

Rare diseases (RD) are diseases that affect not more than 5 per 10 000 persons (according to the EU definition). 7000 distinct rare diseases exist, affecting between 6% and 8% of the population (about 30 million EU citizens). The lack of specific health policies for rare diseases and the scarcity of the expertise, translate into delayed diagnosis, few medicinal products and difficult access to care. That is why rare diseases are a prime example of a research area that strongly profits from coordination on a European scale. At present only few European countries fund research on rare diseases through specific dedicated programmes. Therefore, the funding of transnational collaborative research is the most effective joint activity to enhance the cooperation between scientists working on rare diseases in Europe and beyond. The E-Rare consortium was built to link responsible funding bodies that combine the scarce resources and fund rare disease research via Joint Transnational Calls (JTCs). The current E-Rare-3 pr

M-ERA.NET 3 aims at coordinating the research efforts in the participating EU Member States, Regions, and Associated States in materials research and innovation, including materials for future batteries, to support the circular economy and Sustainable Development Goals. A large network of national and regional funding organisations from 25 EU Members States, 4 Associated States and 6 countries outside Europe will implement a series of annual joint calls to fund excellent innovative transnational RTD cooperation, including one call for proposals with EU co-funding and additional non-cofunded calls. Continuing the activities started under the predecessor project M-ERA.NET 2 (3/2016-2/2021), the M-ERA.NET 3 consortium will address emerging technologies and related applications areas, such as - for example- surfaces, coatings, composites, additive manufacturing or integrated materials modelling. Research on materials supporting the large scale research initiative on future battery technologies will be particularly highlighted as a main target of the cofunded call (Call 2021) with a view to supporting in particular SDG 7 (“Affordable and clean energy”) by enabling electro mobility through sustainable energy storage technology and SDG 9 (“Industrial innovation and infrastructure”) by enhancing scientific research and upgrading the technological capabilities of industrial sectors. Several relevant action plans and initiatives will serve as programmatic guides for M-ERA.NET 3 when defining the joint activities, such as the Circular Economy Action Plan, the 2030 Agenda for Sustainable Development and its 17 Sustainable Development Goals, the EC communication “A clean planet for all”, and the “European Green Deal”. The total mobilised public call budget is expected to reach 150 million € with additional private investment of 50 million €. Thus, the leverage effect of the EU contribution will reach a factor of 13, exceeding by far the minimum required factor of 5.